Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Focal segmental glomerulosclerosis, Steroid-resistant nephrotic syndrome, and Inner ear hearing loss (sensorineural hearing impairment); and common findings: Stage 5 chronic kidney disease. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 5 | Stage 5 chronic kidney disease, Focal segmental glomerulosclerosis, Protein in the urine (proteinuria) |
COQ6 encodes coenzyme Q6, monooxygenase (468 aa). FAD-dependent monooxygenase required for two non-consecutive steps during ubiquinone biosynthesis. Highest expression in Adrenal Gland (33.5 TPM) and Testis (32.4 TPM).
Familial steroid-resistant nephrotic syndrome with sensorineural deafness is associated with mutations in the COQ6 gene on chromosome 14.
The COQ6 protein participates in COQ6 hydroxylates DHB, Unknown enzyme hydroxylates DMPhOH, and Ubiquinol biosynthesis pathways.
COQ6 is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for COQ6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 very common features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for familial steroid-resistant nephrotic syndrome with sensorineural deafness.
10 publications have been identified in PubMed for familial steroid-resistant nephrotic syndrome with sensorineural deafness. Research spans Case Report / Case Series (56%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (22%).
Distelmaier F (2026). [PMID: 40929079](https://pubmed.ncbi.nlm.nih.gov/40929079/). *Brain*. [Case Report / Case Series]
Hahn W (2026). [PMID: 41716779](https://pubmed.ncbi.nlm.nih.gov/41716779/). *Mol Genet Metab Rep*. [Case Report / Case Series]
Torra R (2025). [PMID: 40115110](https://pubmed.ncbi.nlm.nih.gov/40115110/). *Clin Kidney J*. [Review / Meta-Analysis]
Wongkittichote P (2025). [PMID: 41199775](https://pubmed.ncbi.nlm.nih.gov/41199775/). *JIMD Rep*. [Basic Science / Preclinical]
Shi G (2025). [PMID: 40634618](https://pubmed.ncbi.nlm.nih.gov/40634618/). *Nature*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:39 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Brain and nerves | 1 | Seizure |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Age of onset: adolescence.
Sun LY (2024). [PMID: 39563056](https://pubmed.ncbi.nlm.nih.gov/39563056/). *Zhonghua Er Ke Za Zhi*. [Review / Meta-Analysis]
Sun L (2024). [PMID: 38838054](https://pubmed.ncbi.nlm.nih.gov/38838054/). *Nephrology (Carlton)*. [Case Report / Case Series]
Marchini M (2024). [PMID: 39931965](https://pubmed.ncbi.nlm.nih.gov/39931965/). *G Ital Nefrol*. [Case Report / Case Series]
Büyükyılmaz G (2024). [PMID: 39387423](https://pubmed.ncbi.nlm.nih.gov/39387423/). *Turk J Pediatr*. [Case Report / Case Series]